Professional Documents
Culture Documents
Patient
Amy Huberman, MD
Objectives
Reassurance-seeking
Delusions
• Recognized as patient’s own except in cases of thought insertion
• Recognized as justified or even self-evident
• Not resisted
• Believed with conviction
If in doubt:
– Look for accompanying compulsions
– Administer a YBOCS
– Try treating it like OCD, just in case
Second-generation antipsychotics can cause
obsessive-compulsive symptoms
SGAs, and especially clozapine, have been associated
with treatment-emergent obsessive-compulsive
symptoms (Laroche and Gaillard, 2016). Symptoms
appear over 4 weeks to 12 months. Try:
– Decreasing dose of SGA
– Switching to a different neuroleptic
– Adding aripiprazole
– Adding an SSRI
– Cognitive behavioral therapy
Panic Disorder
Thoughts Feelings Behaviors
“I’ll have a heart attack.” Fear of panic-related Avoidance of physical
symptoms and/or their sensations associated with
“I’ll go crazy.” consequences. panic.
“I’ll lose control.”
Use of safety behaviors to
“I’ll faint.” reduce the perceived risk of
experiencing panic.
“I’ll die.”
The Agoraphobia Scale is a useful measure for aiding in the assessment of agoraphobia.
Agoraphobia can occur without
Panic Disorder—and vice versa
Agoraphobia is a fear of not being able to escape or get help in
certain situations in the event of any sort of incapacitating or
embarrassing symptom attack. Feared symptoms are often
panic symptoms but could also be:
Incontinence of bladder or bowel
Vertigo or loss of balance
Nausea or vomiting
There is also evidence for considerable genetic overlap between the two
disorders (Duncan et al, 2018).
Distracting
Irritable behavior
THOUGHTS
MEMORIES
PHYSICAL
SENSATIONS
AVOIDANCE
(provides momentary MISINTERPRETATION
relief from fear but Fear response ratchets up OF SITUATION AS
prevents corrective DANGEROUS
learning)
CBT Disrupts the Anxiety Cycle
It works by encouraging patients to
approach anxiety willingly.
When they stop avoiding their fears,
they learn that they can face them courageously
and come out OK.
Thus, any approach whose goal is to take
away patients’ anxiety—rather than
encourage them to face it—is doomed to fail.
Medication-management of anxiety disorders
• SSRIs have the most evidence.
– Higher doses are often needed for maximal benefit, especially in
OCD (e.g., escitalopram 60 mg, fluoxetine 120 mg, sertraline 400
mg).
– In panic disorder and whenever there is anxiety about possible
side effects, start at the lowest possible dose to avoid activation.
Liquid formulations can be used to achieve low doses (e.g.,
escitalopram 1 mg).
– Watch out for cytochrome P450 interactions and Qct prolongation.
Medication-management of anxiety disorders
• Other medications also have some evidence:
– Clomipramine for OCD (up to 250 mg) and imipramine for panic
disorder. Again, watch the Qct.
– MAOIs for social anxiety (beware of food and drug interactions).
– SNRIs or mirtazapine.
– Augmentation with neuroleptics (trifluoperazine or quetiapine for
GAD; aripiprazole or risperidone for OCD or SAD)
– Benzodiazepines can play a role in short-term management of anxiety,
but beware of long-term use (risk of dependence, falls, problems with
memory, interference with the efficacy of exposure therapy).
– Beware of gabapentin and pregabalin for similar reasons.
Management of Secondary Anxiety
• First priority: treat or manage the underlying cause.
• Can also use the following modalities:
– Pet therapy
– Music therapy
– Yoga
– Guided relaxation
– Mindfulness practice
– Aromatherapy (lavender, rose, citrus, geranium)
In Conclusion